“As a result of Lewis solely complained of regulatory, reasonably than fraudulent, violations in his inside communications with AbbVie, the corporate had no cause to assume Lewis’s considerations revolved across the False Claims Act. Extra merely, AbbVie couldn’t have retaliated in opposition to Lewis as a fraud whistleblower as a result of he by no means blew the whistle on fraud, U.S. Courtroom of Appeals for the Seventh Circuit Choose Joshua P. Kolar mentioned.
Trending
- UK drug price rises ‘necessary’, says Lord Patrick Vallance
- 5 Photography Gimmicks That Went Nowhere
- Things Aren’t Cool At Cooley — See Also
- OpenAI Looks to Build In-House Ad Infrastructure
- Google Search Live is live in U.S., with voice and camera AI mode
- Midwest Fujifilm Shooters Can Check Out This Fun ‘Create With Us’ Event This Weekend
- Are Christmas ads doomed this year?
- Environment Agency failed to visit serious pollution incidents, leaked files show